IMI EHDEN presents their online roadshow : a series of 3 webinars focussed on ‘The Role of Health Data in the Post Covid-19 Era’ Webinar #2: Determining value for patients and harnessing RWE 22 October 14-15h CET With [...]
About bsbhThis author has not yet filled in any details.
So far bsbh has created 232 blog entries.
A series of 3 webinars focussed on
‘The Role of Health Data in the Post Covid-19 Era’
Goal of the webinar series:
The webinars will present an opportunity to explore utilisation of Real World Data/Real World Evidence in Spain and Spanish-speaking countries, as well as to compare and analyse wider European and Spanish RWD/RWE initiatives in the spirit of creating collaborations and strengthening relationships.
IMI EHDEN presents their online roadshow : a series of 3 webinars focussed on ‘The Role of Health Data in the Post Covid-19 Era’ Webinar #1: The need for health data in the era of Covid-19 9 October, 14.30-15.30 CET [...]
9 September, 2020, 8.30 CET
Cancer is still often considered a death sentence. It is the second leading cause of death globally and will soon overtake cardiovascular disease as the number one killer. As a result, the main effect that people expect treatments to have is to prolong overall survival either through curing the disease or by slowing its progression and reducing cancer-related symptoms. Indeed, great progress has been made in recent years and cancer mortality grows at a much slower pace than cancer incidence.
This webinar intends to discuss different perspectives on how funding decisions should be approached depending on the setting of the disease.
15 July, 15.00-16.00 CET
This year more than half a million Europeans will be diagnosed with lung cancer. While many countries have improved the management of lung cancer through better prevention, detection, diagnosis and treatment, the disease continues to claim 1 in 5 cancer deaths across Europe, posing significant challenges to patients and healthcare systems. To identify further opportunities for improvement, The Economist Intelligence Unit made a comparative analysis of lung cancer policies across 27 countries. Over the course of 18 months almost 200 experts provided their insights and advice. During this webinar we will discuss the main findings of this new, landmark study, and discuss in particular the role that governments and policy makers can play in addressing the high burden that lung cancer presents.
8th July, 2020, 08:30 – 09:00 CET
H&N patients haven´t seen innovation in the disease area for the past 10 years. Those patients face stigma and lack of clear pathways to get early treatment. Are we all doing enough to accelerate the process? How do we make others SEE them?
17th June 2020, 11.00-12.00 CET
While Europe is working on creating a Cancer Plan, many Member States have national cancer plans and other ambitious initiatives. For example, Germany that is one year into its Decade Against Cancer. German institutions for research and healthcare, the private sector, political institutions and civil society are joining forces for cancer research, cancer prevention and improved therapy of cancer patients. Germany aims to cure or control cancer long-term in 75% of patients by 2030.
What can Europe learn from Germany, and what are the key success factors for a government driven multi-stakeholder action to improve cancer care?
10th June, 2020, 08:30 – 09:00 CET
Lung cancer is responsible for 1 in 5 cancer deaths in Europe. Last year, around half a million Europeans were diagnosed with lung cancer and 400,000 people died of the disease. The survival rates are quite low, but thanks to improvements in diagnosis, surgery, radiotherapy and medicines, they are getting better. The question is, should we screen more aggressively for lung cancer now, or not?.
20th December 2019, 9am CET
In France, it takes 530 days between market authorisation and patients having access to a new medicine. It’s 374 days in Spain, 111 in the UK, and 106 in Germany. In this webinar we discuss the current access challenges to access to new, innovative oncology treatments in Europe, as well as reforming processes to make reimbursement pathways clearer and more efficient. The objective is to foster timely and appropriate access for those patients with unmet medical needs, and increased clarity and certainty around regulatory access decisions.
Strategic Medicare Contracting Forum – Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
21 November 2019 2.15pm ET
Vital Transformation has conducted two studies examining the impact of the proposed international reference pricing in Medicare Part D on the world-class innovative biotechnology sector in California and the United States.